Thanks for your interest in the CMC Market Outlook newsletter. You may also be interested in these resources:
CMC Market Outlook Sign up to get expert insights
For buyers and sellers of CMC drug development services.
M&A in the CMC Services Industry: Implications and Outlook
In the three-year period 2014-2016 there were 101 acquisitions of CMC services companies, including dose and API manufacturing, packaging, logistics, formulation and analytical services. Learn how M&A in the bio/pharma contract services industry is likely to play out over the next two years.
PharmSource’s Jim Miller Comments on One of the Fastest Growing Areas in Pharma
Jim was recently interviewed about the finished dosage formulations (FDF) market. He spoke about the implications the demand for finished dose formulations is having on the CMO industry and…
Read the interview.
PharmSource’s Jim Miller Comments on Importance of Green Credentials to CMOs
Jim was recently interviewed about environmental concerns in bio/pharmaceutical outsourcing. He spoke about the implications that drug manufacturing has on the environment and how process chemists work to refine or… Read the interview.
Biggest story in contract services market since 2014
Overall flow of money into early stage bio/pharma companies and acquisition activity in the industry… Jim Miller’s perspective
Catching a Wave: How Much Will CMOs Benefit From Biosimilars?
The second wave of biosimilars is starting to hit US and European markets. Biopharma companies are already starting to develop the third wave. What can CMOs do to get a bigger piece of the future opportunity?
Contract Manufacturing of Conventional Injectable Drugs Through 2019
This extensive study estimates the demand for contract injectable manufacturing through 2019. Learn more about the latest trends for outsourcing of commercially approved injectable products.
PharmSource President Jim Miller Interviewed on Capital Expenditure Trends
Jim was recently interviewed about PharmSource’s CapEx Trend Report. He spoke about the implications that emerged from PharmSource’s research on nearly 250 public companies, including on CMO capacity expansion… Read the interview.
Future of CMO Cytotoxic Injectables Capacity
The cytotoxic CMO industry has lost considerable capacity in recent years. While at least 21 CMOs claim to offer capacity for cytotoxic injectables, only five have the capabilities, track record and market focus to be considered for manufacture of high value cytotoxic products like ADCs. Learn why the pipeline of ADCs in late development is very limited.